Isofol Medical: Fully focused on AGENT - DNB

Thursday, February 20, 2020 7:51 AM
"Q4’s operating loss was higher than expected, mainly due to continued higher R&D spending as well as costs related to the change of CEO. The 005-study has been concluded and the company’s full attention should now be on bringing arfolitixorin to market. We estimate continued high R&D spending going forward as more sites are expected to be opened. We have tweaked our estimated fair value to SEK14–42 (SEK18–49)."

Link to commissioned research below.